Increased number of CD16+CD56dim NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation

Tanaka, Junji; Sato, Junichi; Asanuma, Shinsuke; Arita, Kotaro; Shono, Yusuke; Kikutchi, Misato; Shiratori, Souichi; Wakasa, Kentaro; Yasumoto, Atsushi; Shigematu, Akio; Kondo, Takeshi; Kobayashi, Takahiko; Asaka, Masahiro; Imamura, Masahiro

doi:10.1016/j.humimm.2009.06.002

Cited by 13 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However it is also possible that more prompt recovery of NK cells and B-cells in UCB recipients may compensate for early T-cell deficits, although rapid recovery of both of these cell types may partly be due to a compensatory response to the profound T-lymphopenia [37, 38]. Tanaka et al observed a more rapid expansion of NK cells following umbilical cord blood compared to peripheral blood stem cell transplantation [39]. The investigators found that a umbilical cord blood derived mature (CD16+, CD56 dim ) and immature (CD16−, CD56+) populations of NK cells exert potent cytotoxic activity against tumor cell lines and exhibit decreased expression of inhibitory NKG2A and increased expression of stimulatory NKG2C as compared to NK cells that emerge following matched related donor transplantation.…”

Section: Discussionmentioning

confidence: 99%

Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation

Kanda

Chiou

Szabolcs

et al. 2012

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation

Kanda

Chiou

Szabolcs

et al. 2012

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

“…18, 19 NK cell engraftment is earlier and more robust and T-cell engraftment is delayed after CBT. 20, 21 Therefore, CBT may represent a setting in which KIR ligand incompatibility is associated with protection from leukemia relapse. Willemze et al 22 reported transplantation outcomes after single-unit CBT for AML patients ( n =94) and ALL patients ( n =124).…”

Section: Discussionmentioning

confidence: 99%

Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission

Tanaka

Morishima

Takahashi

et al. 2013

Blood Cancer Journal

View full text Add to dashboard Cite

To clarify the effect of killer cell immunoglobulin-like receptor (KIR) ligand incompatibility on outcomes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients in complete remission after single cord blood transplantation (CBT), we assessed the outcomes of CBT registered in the Japan Society for Hematopoietic Cell Transplantation (JSHCT) database. A total of 643 acute leukemia (357 AML and 286 ALL) patient and donor pairs were categorized according to their KIR ligand incompatibility by determining whether or not they expressed HLA-C, Bw4 or A3/A11 by DNA typing. A total of 128 patient–donor pairs were KIR ligand-incompatible in the graft-versus-host (GVH) direction and 139 patient–donor pairs were incompatible in the host-versus-graft (HVG) direction. Univariate and multivariate analyses showed no significant differences between the KIR ligand-incompatible and compatible groups in the GVH direction for both AML and ALL patients of overall survival, disease-free survival, relapse incidence, non-relapse mortality and acute GVH disease. However, KIR incompatibility in the HVG direction ameliorated engraftment in ALL patients (hazard ratio 0.66, 95% confidence interval 0.47–0.91, P=0.013). Therefore, there were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use. However, it is necessary to pay attention to KIR incompatibility in the HVG direction for engraftment.

show abstract

“…7,10 Conversely, innate immunity recovery has been shown to be similar between CB and BM recipients, with normal cell counts of functional NK cells in the blood as soon as 1-month post-CBT. 2,11,12 Finally, B-cell number recovery appears to be faster after CBT. 6,9,13 Besides these differences in the reconstitution of the major lymphocyte populations, additional changes in the reconstitution of other immune cell subsets might occur and explain some of the clinical differences observed in patients who receive BMT or CBT.…”

Section: Introductionmentioning

confidence: 95%

Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children

Charrier

Cordeiro

Brito

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Some clinical characteristics of cord blood transplantation (CBT) might be explained by specificities in the reconstitution of immune subsets differing by their maturation stage or their implication in GVHD, tolerance or immune responses against tumor or infectious agents. Here, we compare the immune reconstitution of several of these subsets after CBT and BMT. B-cell count recovery was faster after CBT. There was no difference in the recovery of CD4 þ and CD8 þ cell counts. There was no difference either in the frequency of several subsets: CD45RO þ memory, and CD45RA þ naïve cells within the CD4 þ T-cell compartment, CD27 þ among B cells, CD56 bright , NKG2A þ , and KIR þ cells among natural killer (NK) cells, CD25 þ FOXP3 þ regulatory T cells and invariant NKT cells. The proportion of the thymic naïve CD31 þ CD45RA þ CD4 þ T cells was lower after CBT at 6 months post-transplant, and was still below normal at 1 year in both groups. NK-cell expansion was more sustained after CBT, with fewer double-negative NKG2A À KIR À hyporesponsive cells and more double-positive NKG2A þ KIR þ hyper-responsive NK cells. These results, therefore, indicate that further research to improve CBT outcome should try to improve thymopoieisis and take advantage of the sustained NK-cell reconstitution. INTRODUCTIONAlmost all lethal complications of hematopoietic SCT, including leukemia relapse, and opportunistic infections, result from the post-transplant immune deficiency that lasts for months after transplantation. Therefore, the therapeutic challenge in improving the outcome for transplanted children outcome relies on the enhancement of immune reconstitution and the GVL effect, without increasing the harmful GVHD.Although lower rates of engraftment and GVHD and higher rates of life-threatening infections have been reported in patients who received cord blood transplantation (CBT), similar EFS and leukemia relapse rates have been observed after CBT and BMT. [1][2][3][4][5] These observations indicate that cord blood-derived immune cells have unique immune properties that allow for allogeneic tolerance while preserving the GVL effect.Previous studies have compared the reconstitution of the major immune cell populations after CBT and BMT: CD4 þ and CD8 þ T cells, natural killer (NK) and B cells. They showed that T-cell recovery is delayed, in particular CD8 þ T-lymphopoiesis after CBT, 2,6-9 although T-cell diversity has been shown to be similar in cord blood (CB) and BM recipients beyond 1 year after transplant. 7,10 Conversely, innate immunity recovery has been shown to be similar between CB and BM recipients, with normal cell counts of functional NK cells in the blood as soon as 1-month post-CBT. 2,11,12 Finally, B-cell number recovery appears to be faster after CBT. 6,9,13 Besides these differences in the reconstitution of the major lymphocyte populations, additional changes in the reconstitution of other immune cell subsets might occur and explain some of the clinical differences observed in patients who receive BMT or CBT.

show abstract

Increased number of CD16+CD56dim NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation

Cited by 13 publications

References 25 publications

Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation

Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation

Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission

Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children

Contact Info

Product

Resources

About